Analysts Conflicted on These Healthcare Names: Day One Biopharmaceuticals (DAWN), Fresenius Medical Care (FMS) and BridgeBio Pharma (BBIO)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Day One Biopharmaceuticals (DAWN – Research Report), Fresenius Medical Care (FMS – Research Report) and BridgeBio Pharma (BBIO – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Day One Biopharmaceuticals (DAWN)
Wedbush analyst Robert Driscoll reiterated a Buy rating on Day One Biopharmaceuticals today and set a price target of $30.00. The company’s shares closed last Tuesday at $12.02.
According to TipRanks.com, Driscoll is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Day One Biopharmaceuticals with a $22.14 average price target, an 87.9% upside from current levels. In a report issued on February 23, JonesTrading also maintained a Buy rating on the stock with a $20.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Fresenius Medical Care (FMS)
In a report released today, David S Macdonald from Truist Financial maintained a Hold rating on Fresenius Medical Care. The company’s shares closed last Tuesday at $22.66.
According to TipRanks.com, Macdonald is a 5-star analyst with an average return of
The the analyst consensus on Fresenius Medical Care is currently a Hold rating.
BridgeBio Pharma (BBIO)
In a report released today, Danielle Brill from Truist Financial reiterated a Buy rating on BridgeBio Pharma, with a price target of $95.00. The company’s shares closed last Tuesday at $68.31.
According to TipRanks.com, Brill is a 4-star analyst with an average return of
BridgeBio Pharma has an analyst consensus of Strong Buy, with a price target consensus of $103.00, implying a 51.7% upside from current levels. In a report issued on February 12, TD Cowen also maintained a Buy rating on the stock with a $95.00 price target.
